Circulating metabolites serve as diagnostic biomarkers for HER2-positive breast cancer and have predictive value for trastuzumab therapy outcomes.

Mao, Changfei; Wang, Min; Li, Li; Tang, Jin-Hai

Mao, Changfei; Wang, Min; Li, Li; Tang, Jin-Hai.

Afiliación

Mao C; Department of General Surgery, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Nanjing, China.
Wang M; Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Li L; Department of General Surgery, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Nanjing, China.
Tang JH; Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

J Clin Lab Anal ; 36(2): e24212, 2022 Feb.

Article en En | MEDLINE | ID: mdl-34994982

Asunto(s)

Antineoplásicos Inmunológicos/uso terapéutico; Biomarcadores de Tumor/sangre; Neoplasias de la Mama/sangre; Trastuzumab/uso terapéutico; Adulto; Anciano; Neoplasias de la Mama/diagnóstico; Neoplasias de la Mama/tratamiento farmacológico; Estudios de Casos y Controles; Femenino; Humanos; Persona de Mediana Edad; Pronóstico; Receptor ErbB-2

Palabras clave

HER2-positive breast cancer; metabolic biomarkers; metabolomics; trastuzumab therapy outcomes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Biomarcadores de Tumor / Trastuzumab / Antineoplásicos Inmunológicos Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: J Clin Lab Anal Asunto de la revista: TECNICAS E PROCEDIMENTOS DE LABORATORIO Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google